Compare Cassava Sciences Inc (FLNA) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Raymond James Financial, Inc. — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Raymond James Financial, Inc. trades at $169.54 (market cap $33.19B). The key difference: Raymond James Financial, Inc. is far larger — about 624.6× Cassava Sciences Inc's market cap, and Raymond James Financial, Inc. pays a 1.27% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | RJF | |
|---|---|---|
Market Cap | $53.14M | $33.19B |
Sector | Health | Financials |
52-Week High | $4.64 | $176.43 |
52-Week Low | $1.09 | $140.89 |
Enterprise Value | -$33.43M | — |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
Raymond James Financial (RJF) trades at $167.43, up 0.27% today, with a bullish technical signal and consistent earnings beats. Revenue grew to $13.84B in 2025, though net income margin dipped slightly to 15.42%. The stock is supported by a consensus price target of $176.83 and a declared $0.54 dividend payable in July 2026.
The outlook remains positive with strong analyst support and record revenues, but rising expenses and a high RSI near 75 indicate potential near-term volatility. Long-term growth is supported by advisor expansion and strategic acquisitions, though cost management remains a key focus for sustained profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
